The DoD’s Amyotrophic Lateral Sclerosis Therapeutic Idea Award (TIA) aims to fund conceptually innovative, high-risk/high-reward research for novel ALS treatments. This grant supports new ideas in their early developmental stages that hold potential for highly impactful data and new avenues of investigation with translational promise. Proposed projects must feature a well-formulated, testable hypothesis, avoiding a primary focus on ALS pathophysiology. While preliminary data is not prohibited, the application’s strength should not rely on it. Innovation, such as introducing new paradigms or novel concepts, and significant impact on ALS therapeutic development and clinical translation are paramount for this award. It specifically excludes incremental advancements or standard screening projects.
Opportunity ID: 233013
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-13-ALSRP-TIA |
| Funding Opportunity Title: | DoD Amyotrophic Lateral Sclerosis Therapeutic Idea Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 2 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | May 03, 2013 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Sep 18, 2013 |
| Current Closing Date for Applications: | Sep 18, 2013 |
| Archive Date: | Oct 18, 2013 |
| Estimated Total Program Funding: | $1,200,000 |
| Award Ceiling: | $0 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The ALSRP Therapeutic Idea Award (TIA) mechanism was first offered in FY10. Since then, 113 TIA applications have been received, and 11 have been recommended for funding. The TIA is designed to promote new ideas that are still in the early stages of development with the potential to yield highly impactful data and new avenues of investigation for novel therapeutics for ALS treatment. This mechanism supports conceptually innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancement in ALS therapeutics. Proposed research projects should include a well-formulated, testable hypothesis based on strong scientific rationale that holds translational potential to improve ALS treatment and/or advances a novel treatment modality. Projects that focus primarily on investigating the pathophysiology of ALS are outside the scientific scope of this mechanism. Presentation of preliminary data is not consistent with the intent of the Therapeutic Idea Award mechanism. While the inclusion of preliminary data is not prohibited, the strength of the application should not rely on preliminary data. Innovation and impact are the most important aspects of the TIA. Innovation: Research deemed innovative may introduce a new paradigm, challenge current paradigms, introduce novel concepts or agents, or exhibit other uniquely creative qualities that may lead to potential therapeutics for ALS. The following list, although not all-inclusive, provides examples of research that is NOT innovative and will not be considered for funding under this mechanism: Investigating the next logical step or continuation of a previous or ongoing research project. Proposing work that is an incremental advancement of published data. Proposing a project whose scope is primarily small-molecule or genomic/proteomic screening. Exploring a previously tested hypothesis in a different cell line or in a new population. Using a published series of in vitro assays to further characterize a model system. Incorporating known biomarkers into in vitro or clinical models of ALS. Impact: The ALSRP TIA aims to support research that has high potential to significantly impact development of therapeutics for ALS. Potential therapeutic impact as well as steps toward clinical translation of projected study outcomes should be outlined in the Impact/Transition Statement (Attachment 6) for the application. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
301-682-5507 Email:help@cdmrp.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 233013 Full Announcement-1 -> fy13 cdmrp gai_2may2013.pdf
Folder 233013 Full Announcement-1 -> alsrp fy13 tia pa_gg.pdf
Packages
| Agency Contact Information: | CDMRP Help Desk 301-682-5507 Email: help@cdmrp.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00176270 | May 03, 2013 | Sep 18, 2013 | View |
Package 1
Mandatory forms
233013 RR_SF424_1_2-1.2.pdf
233013 PerformanceSite_1_4-1.4.pdf
233013 RR_Budget-1.1.pdf
233013 RR_KeyPersonExpanded_1_2-1.2.pdf
Optional forms
233013 RR_SubawardBudget30-1.2.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
